11 completed. 4 Phase 3, 3 Phase 1, 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow norelgestromin: new trials by email Literature Review of norelgestromin trials Research Report on norelgestromin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Birth Control Patch Study Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016), Norelgestromin/Ethinylestradiol (EVRA) - Contraception | Phase 3 | Completed | Bayer | 393 | 2009-05-01 | 2014-04-02 |
| Bioequivalence Study of Patches With Different Equilibration Profiles norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system. - Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 42 | 2004-05-01 | 2011-06-08 |
| A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive) EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets). - Contraception, Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 60 | 2004-05-01 | 2011-06-08 |
| Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception. norelgestromin + ethinyl estradiol - Contraception, Female Contraception | Phase 4 | Completed | Janssen Pharmaceutica N.V., Belgium | 778 | 2003-07-01 | 2010-11-16 |
| Birth Control Pill vs Birth Control Patch Study Ethinyl estradiol and norgestimate, Ethinyl estradiol and norelgestromin - Venous Thrombosis | Not applicable | Completed | University of Vermont | 24 | 2003-04-01 | 2007-11-07 |
| An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method norelgestromin; ethinyl estradiol - Female Contraception | Phase 4 | Completed | Janssen-Ortho Inc., Canada | 405 | 2002-10-01 | 2010-03-26 |
| A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets). - Contraception, Female Contraception | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 34 | 2002-08-01 | 2011-06-08 |
| A Study of Efficacy and Safety With the Transdermal Contraceptive System. norelgestromin + ethinyl estradiol - Contraception, Female Contraception | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1751 | 1997-11-01 | 2010-11-17 |
| A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon. norelgestromin + ethinyl estradiol; mercilon - Contraception | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1517 | 1997-10-01 | 2011-06-08 |
| A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. norelgestromin + ethinyl estradiol; triphasil. - Contraception, Female Contraception | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1494 | 1997-01-01 | 2011-06-08 |
| An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen norelgestromin/ethinyl estradiol - Metrorrhagia | Phase 2 | Completed | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | 239 | 2011-07-01 |
Hemorrhage (1) · Metrorrhagia (1) · Venous Thrombosis (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Bayer (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen-Ortho Inc., Canada (1) · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. (1) · University of Vermont (1)
Austria (1) · Czechia (1) · Netherlands (1)
PMID 11849631, PMID 11849634, PMID 11704172, PMID 15932834, PMID 15937609, PMID 15950671, PMID 18238963, PMID 25453582
2008 (1)